Claims for Patent: 10,293,037

Summary for Patent: 10,293,037

Title:	DNA vaccine for use in pancreatic cancer patients
Abstract:	The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.
Inventor(s):	Lubenau; Heinz (Neustadt an der Weinstrasse, DE)
Assignee:	VAXIMM AG (CH)
Application Number:	15/994,766
Patent Claims:	1. A method of providing cancer immunotherapy comprising administering to a patient suffering from a cancer, a DNA vaccine comprising an attenuated mutant strain of Salmonella typhi Ty21a comprising an expression cassette encoding a human VEGFR-2 having the amino acid sequence of SEQ ID NO 1, wherein a single dose of the vaccine is 10.sup.9 colony forming units (CFU) or less than 10.sup.9 CFU. 2. The method of claim 1, wherein the expression cassette is a eukaryotic expression cassette. 3. The method of claim 2, wherein the cancer immunotherapy is an anti-angiogenic cancer immunotherapy and wherein the DNA vaccine comprises the attenuated Salmonella typhi strain Ty21a transformed by a plasmid that contains the DNA encoding the VEGFR-2 protein of SEQ ID NO 1. 4. The method of claim 3, wherein the plasmid is the 7580 bp pVAX10.VR2-1 having the sequence of SEQ ID NO 3. 5. The method of claim 1, wherein the cancer is pancreatic cancer. 6. The method of claim 5, wherein said pancreatic cancer is stage IV or locally advanced pancreatic cancer. 7. The method of claim 1, wherein the cancer includes metastases. 8. The method of claim 1, further comprising administering to the patient chemotherapy and/or radiotherapy. 9. The method of claim 8, wherein the chemotherapeutic agent is gemcitabine. 10. The method of claim 8, wherein the administration of the DNA vaccine is carried out during the chemotherapy treatment cycle. 11. The method of claim 1, wherein the DNA vaccine is administered orally. 12. The method of claim 1, wherein the single dose of the vaccine is a dose selected from the group of: 1.times.10.sup.5, 1.times.10.sup.6, 1.times.10.sup.7, 1.times.10.sup.8, and 1.times.10.sup.9 CFU. 13. The method of claim 1, wherein the single dose of the vaccine is less than 1.times.10.sup.9 CFU. 14. The method of claim 1, wherein the single dose of the vaccine is less than 1.times.10.sup.8 CFU. 15. The method of claim 1, wherein the single dose of the vaccine comprises from 10.sup.6 to 10.sup.9 CFU. 16. A method of providing cancer immunotherapy to a cancer patient comprising administering to the patient a DNA vaccine VXM01, comprising the attenuated Salmonella typhi strain Ty21a transformed by a 7580 bp plasmid, the plasmid comprising a DNA encoding the VEGFR-2 protein of SEQ ID NO 1 under the control of a CMV promoter, the kanamycin resistance gene, and the pMB1 ori, and is designated as pVAX10.VR2-1, and wherein a single dose of the vaccine is 10.sup.9 CFU or less than 10.sup.9 CFU. 17. The method of claim 1, wherein the single dose of the vaccine comprises from 10.sup.6 to 10.sup.8 CFU. 18. The method of claim 1, wherein the method further comprises administering to the patient one or more further attenuated mutant strains(s) of Salmonella typhi Ty21a comprising a eukaryotic expression cassette encoding a tumor antigen and/or a tumor stroma antigen.

Details for Patent 10,293,037

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bavarian Nordic A/s	VIVOTIF	typhoid vaccine live oral ty21a	Capsule	103123	December 15, 1989		2032-07-05